STANDARD BIOTOOLS INC. — Director's Dealing 2024

Jul 2, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2024-06-28

Reporting Person: Casdin Eli (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-28	Common Stock	A	43128	—	Acquired	2750744	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-28	Stock Option (Right to buy)	$1.77	A	72213	Acquired	2034-06-28	Common Stock (72213)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13939637	Indirect
Common Stock	2744219	Indirect
Common Stock	18870	Indirect
Common Stock	46730821	Indirect
Common Stock	545000	Indirect

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

F2: Includes 2,604,060 shares of common stock received in a pro rata distribution for no consideration by C-LSH II LLC in accordance with the exemptions afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

F3: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

F4: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

F5: The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities.

F6: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F7: The securities are owned directly by Casdin Amplify Fund, LP ("Amplify") and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin and the GP.

F8: The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date.